WithdrawnNot Applicable

Comparison of Surgical Treatment Options for Primary Congenital and Developmental Glaucomas

Stopped: Funding for the study could not be found.

0Started 2020-12-01

Plain-language summary

Newborn and children can be affected by two subgroups of this disease: (1) primary congenital glaucoma (PCG) or (2) developmental glaucoma (DG). The primary aim of this study is to compare the Santen PRESERFLO implant to trabeculectomy in PCG and DG patients as second surgery after failed trabeculotomy or goniotomy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Minors younger than 18 years of age with a diagnosis of Primary Congenital Glaucoma (PCG) or Developmental Glaucoma (DG) will be included * participants must have had a failed trabeculotomy or goniotomy (once or twice) or one 360° trabeculotomy. Exclusion Criteria: * Individuals with eye pathologies other than glaucoma or, who underwent intraocular surgery within the last 6 months will not be included. * patients who will not be willing to proceed with the entire follow-up of 6 months, or whose legal representative did not sign the informed consent will not be enrolled.

What they're measuring

Efficacy 1

Timeframe: at 6months compared to baseline (i.e. preop)

Efficacy 2

Timeframe: at 6months compared to baseline (i.e. preop)

Complication rate

Timeframe: within 6 months from surgery

Trial details

NCT IDNCT04647929

SponsorUniversity of Zurich

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-01

View on ClinicalTrials.gov More Primary Congenital Glaucoma trials